Revenue ($USD) : $6,561,297,821
Revenue (foreign currencies) : JP¥921,863,000,000
R&D spend : $491,529,899
Employees : 30,591
CEO : Hikaru Samejima

www.terumo.com

Terumo’s wide range of products include interventional cardiology, blood transfusion and cell therapy. In May 2024, Terumo Cardiovascular announced FDA 510(k) clearance of its CDI OneView cardiopulmonary bypass surgery monitoring system. The next-generation system measures or displays up to 22 vital patient parameters, including oxygen delivery, cardiac index, area under the indexed oxygen delivery curve, oxygen extraction ratio and measured flow. –CN